Generic placeholder image

Current Stem Cell Research & Therapy

Editor-in-Chief

ISSN (Print): 1574-888X
ISSN (Online): 2212-3946

Review Article

MicroRNAs: Crucial Players in the Differentiation of Human Pluripotent and Multipotent Stem Cells into Functional Hepatocyte-Like Cells

Author(s): Hao Xu, Liying Wu*, Guojia Yuan, Xiaolu Liang, Xiaoguang Liu, Zuobiao Li, Nianping Chen and Maryam Farzaneh*

Volume 17, Issue 8, 2022

Published on: 24 November, 2021

Page: [734 - 740] Pages: 7

DOI: 10.2174/1574888X16666211006102039

Price: $65

Abstract

Hepatic disease negatively impacts liver function and metabolism. Primary human hepatocytes are the gold standard for the prediction and successful treatment of liver disease. However, the sources of hepatocytes for drug toxicity testing and disease modeling are limited. To overcome this issue, pluripotent stem cells (PSCs) have emerged as an alternative strategy for liver disease therapy. Human PSCs, including embryonic stem cells (ESC) and induced pluripotent stem cells (iPSC) can self-renew and give rise to all cells of the body. Human PSCs are attractive cell sources for regenerative medicine, tissue engineering, drug discovery, and developmental studies. Several recent studies have shown that mesenchymal stem cells (MSCs) can also differentiate (or trans-differentiate) into hepatocytes. Differentiation of human PSCs and MSCs into functional hepatocytelike cells (HLCs) opens new strategies to study genetic diseases, hepatotoxicity, infection of hepatotropic viruses, and analyze hepatic biology. Numerous in vitro and in vivo differentiation protocols have been established to obtain human PSCs/MSCs-derived HLCs and mimic their characteristics. It was recently discovered that microRNAs (miRNAs) play a critical role in controlling the ectopic expression of transcription factors and governing the hepatocyte differentiation of human PSCs and MSCs. In this review, we focused on the role of miRNAs in the differentiation of human PSCs and MSCs into hepatocytes.

Keywords: Liver diseases, pluripotent stem cells, induced pluripotent stem cells, mesenchymal stem cells, microRNAs, hepatocytes.

[1]
Chan M, So V, Irwin MG. Clinical aspects of hepatic disease. Anaesth Intensive Care Med 2020; 21: 498-502.
[http://dx.doi.org/10.1016/j.mpaic.2020.07.009]
[2]
Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol 2019; 70(1): 151-71.
[http://dx.doi.org/10.1016/j.jhep.2018.09.014] [PMID: 30266282]
[3]
Paglialunga S, Dehn CA. Clinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver disease. Lipids Health Dis 2016; 15(1): 159.
[http://dx.doi.org/10.1186/s12944-016-0321-5] [PMID: 27640119]
[4]
Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol 2012; 56(4): 952-64.
[http://dx.doi.org/10.1016/j.jhep.2011.08.025] [PMID: 22173168]
[5]
Cai J, Zhang X-J, Li H. Role of innate immune signaling in non-alcoholic fatty liver disease. Trends Endocrinol Metab 2018; 29(10): 712-22.
[http://dx.doi.org/10.1016/j.tem.2018.08.003] [PMID: 30131212]
[6]
Hoofnagle JH, Björnsson ES. Drug-induced liver injury-types and phenotypes. N Engl J Med 2019; 381(3): 264-73.
[http://dx.doi.org/10.1056/NEJMra1816149] [PMID: 31314970]
[7]
Andrade RJ, Chalasani N, Björnsson ES, et al. Drug-induced liver injury. Nat Rev Dis Primers 2019; 5(1): 58.
[http://dx.doi.org/10.1038/s41572-019-0105-0] [PMID: 31439850]
[8]
Tricot T, De Boeck J, Verfaillie C. Alternative cell sources for liver parenchyma repopulation: Where do we stand? Cells 2020; 9(3): 566.
[http://dx.doi.org/10.3390/cells9030566] [PMID: 32121068]
[9]
Zhu C, Dong B, Sun L, Wang Y, Chen S. Cell sources and influencing factors of liver regeneration: A review. Med Sci Monit 2020; 26: e929129-1.
[http://dx.doi.org/10.12659/MSM.929129] [PMID: 33311428]
[10]
Ruoß M, Vosough M, Königsrainer A, et al. Towards improved hepatocyte cultures: Progress and limitations. Food Chem Toxicol 2020; 138: 111188.
[http://dx.doi.org/10.1016/j.fct.2020.111188] [PMID: 32045649]
[11]
Jin M, Yi X, Liao W, et al. Advancements in stem cell-derived hepatocyte-like cell models for hepatotoxicity testing. Stem Cell Res Ther 2021; 12(1): 84.
[http://dx.doi.org/10.1186/s13287-021-02152-9] [PMID: 33494782]
[12]
Nozaki Y, Izumi S. Recent advances in preclinical in vitro approaches towards quantitative prediction of hepatic clearance and drug-drug interactions involving organic anion transporting polypeptide (OATP) 1B transporters. Drug Metab Pharmacokinet 2020; 35(1): 56-70.
[http://dx.doi.org/10.1016/j.dmpk.2019.11.004] [PMID: 31901416]
[13]
Izat N, Sahin S. Hepatic transporter-mediated pharmacokinetic drug-drug interactions: Recent studies and regulatory recommendations. Biopharm Drug Dispos 2021; 42(2-3): 45-77.
[http://dx.doi.org/10.1002/bdd.2262] [PMID: 33507532]
[14]
Lu C, Di L. In vitro and in vivo methods to assess pharmacokinetic drug- drug interactions in drug discovery and development. Biopharm Drug Dispos 2020; 41(1-2): 3-31.
[http://dx.doi.org/10.1002/bdd.2212] [PMID: 31778578]
[15]
Maepa SW, Ndlovu H. Advances in generating liver cells from pluripotent stem cells as a tool for modeling liver diseases. Stem Cells 2020; 38(5): 606-12.
[http://dx.doi.org/10.1002/stem.3154] [PMID: 32012379]
[16]
Li W, Li L, Hui L. Cell plasticity in liver regeneration. Trends Cell Biol 2020; 30(4): 329-38.
[http://dx.doi.org/10.1016/j.tcb.2020.01.007] [PMID: 32200807]
[17]
Sadri A-R, Jeschke MG, Amini-Nik S. Advances in liver regeneration: Revisiting hepatic stem/progenitor cells and their origin. Stem Cells Int 2016; 2016: 7920897.
[http://dx.doi.org/10.1155/2016/7920897] [PMID: 26798363]
[18]
Bria A, Marda J, Zhou J, et al. Hepatic progenitor cell activation in liver repair. Liver Res 2017; 1(2): 81-7.
[http://dx.doi.org/10.1016/j.livres.2017.08.002] [PMID: 29276644]
[19]
Chen Q, You X, Yang W, et al. Survival of endogenous hepatic stem/progenitor cells in liver tissues during liver cirrhosis. Life Sci 2020; 241: 117121.
[http://dx.doi.org/10.1016/j.lfs.2019.117121] [PMID: 31794772]
[20]
Yamaguchi T, Matsuzaki J, Katsuda T, Saito Y, Saito H, Ochiya T. Generation of functional human hepatocytes in vitro: Current status and future prospects. Inflamm Regen 2019; 39: 13.
[http://dx.doi.org/10.1186/s41232-019-0102-4] [PMID: 31308858]
[21]
Katsuda T, Kawamata M, Inoue A, Yamaguchi T, Abe M, Ochiya T. Long-term maintenance of functional primary human hepatocytes using small molecules. FEBS Lett 2020; 594(1): 114-25.
[http://dx.doi.org/10.1002/1873-3468.13582] [PMID: 31432507]
[22]
Yao J, Yu Y, Nyberg SL. Induced pluripotent stem cells for the treatment of liver diseases: Novel concepts. Cells Tissues Organs 2020; 209: 1-17.
[http://dx.doi.org/10.1159/000508182] [PMID: 32615573]
[23]
Piscaglia A C, Campanale M, Gasbarrini A, Gasbarrini G. Stem cell-based therapies for liver diseases: state of the art and new perspectives. Stem Cells Intern 2010; 2010: 259461.
[http://dx.doi.org/10.4061/2010/259461]
[24]
Pareja E, Gómez-Lechón MJ, Tolosa L. Induced pluripotent stem cells for the treatment of liver diseases: challenges and perspectives from a clinical viewpoint. Ann Transl Med 2020; 8(8): 566.
[http://dx.doi.org/10.21037/atm.2020.02.164] [PMID: 32775367]
[25]
Shams S, Imran N, Afridi SG, Ayaz M, Khalil AAK, Nasir A. In vitro differentiation effect of CCL4-induced liver injured mice serum on bone marrow-derived mesenchymal stem cells toward hepatocytes like cells. Cell Tissue Bank 2021; 22(2): 297-303.
[http://dx.doi.org/10.1007/s10561-020-09878-5] [PMID: 33169293]
[26]
Serras ASM, Cipriano MZdRF, da Graça Silva PM, Miranda JPG. Challenges for deriving hepatocyte-like cells from umbilical cord mesenchymal stem cells for in vitro toxicology applications. In: Kitala D, AC Maurício, Eds. Novel perspectives of stem cell manufacturing and therapies. UK: Intechopen 2020.
[27]
Nitta S, Kusakari Y, Yamada Y, et al. Conversion of mesenchymal stem cells into a canine hepatocyte-like cells by Foxa1 and Hnf4a. Regen Ther 2020; 14: 165-76.
[http://dx.doi.org/10.1016/j.reth.2020.01.003] [PMID: 32123700]
[28]
Wang H, Tian Y, Li X, Yang M, Yan Y. Amniotic mesenchymal stem cells derived hepatocyte-like cells attenuated liver fibrosis more efficiently by mixed-cell transplantation. Int J Physiol Pathophysiol Pharmacol 2020; 12(1): 11-24.
[PMID: 32211118]
[29]
Hosseini V, Maroufi NF, Saghati S, et al. Current progress in hepatic tissue regeneration by tissue engineering. J Transl Med 2019; 17(1): 383.
[http://dx.doi.org/10.1186/s12967-019-02137-6] [PMID: 31752920]
[30]
Poorna MR, Sudhindran S, Thampi MV, Mony U. Differentiation of induced pluripotent stem cells to hepatocyte-like cells on cellulose nanofibril substrate. Colloids Surf B Biointerfaces 2021; 198: 111466.
[http://dx.doi.org/10.1016/j.colsurfb.2020.111466] [PMID: 33243549]
[31]
Asadi M, Lotfi H, Salehi R, et al. Hepatic cell-sheet fabrication of differentiated mesenchymal stem cells using decellularized extracellular matrix and thermoresponsive polymer. Biomed Pharmacother 2021; 134: 111096.
[http://dx.doi.org/10.1016/j.biopha.2020.111096] [PMID: 33338746]
[32]
Jaafarpour Z, Soleimani M, Hosseinkhani S, et al. Overexpression of microRNA-375 and microRNA-122 promotes the differentiation of human induced pluripotent stem cells into hepatocyte-like cells. Biologicals 2020; 63: 24-32.
[http://dx.doi.org/10.1016/j.biologicals.2019.12.005] [PMID: 31882195]
[33]
Li L, Miu K-K, Gu S, Cheung H-H, Chan W-Y. Comparison of multi-lineage differentiation of hiPSCs reveals novel miRNAs that regulate lineage specification. Sci Rep 2018; 8(1): 9630.
[http://dx.doi.org/10.1038/s41598-018-27719-0] [PMID: 29941943]
[34]
Skrzypczyk A, Kehr S, Krystel I, et al. Noncoding RNA transcripts during differentiation of induced pluripotent stem cells into hepatocytes. Stem Cells Int 2018; 2018: 5692840.
[http://dx.doi.org/10.1155/2018/5692840]
[35]
Arif KMT, Elliott EK, Haupt LM, Griffiths LR. Regulatory mechanisms of epigenetic miRNA relationships in human cancer and potential as therapeutic targets. Cancers 2020; 12(10): 2922.
[http://dx.doi.org/10.3390/cancers12102922] [PMID: 33050637]
[36]
Farzaneh M, Derakhshan Z, Hallajzadeh J, Sarani NH, Nejabatdoust A, Khoshnam SE. Suppression of TGF-β and ERK signaling pathways as a new strategy to provide rodent and non-rodent pluripotent stem cells. Curr Stem Cell Res Ther 2019; 14(6): 466-73.
[http://dx.doi.org/10.2174/1871527318666190314110529] [PMID: 30868962]
[37]
Kolagar TA, Farzaneh M, Nikkar N, Khoshnam SE. Human pluripotent stem cells in neurodegenerative diseases: Potentials, advances and limitations. Curr Stem Cell Res Ther 2020; 15(2): 102-10.
[http://dx.doi.org/10.2174/1574888X14666190823142911] [PMID: 31441732]
[38]
Graffmann N, Spitzhorn L-S, Martins S, Rahman M S, Nguyen L, Adjaye J. Stem cell therapy. In: Vogel HG, Maas J, Gebauer A, Eds. Drug discovery and evaluation: Methods in clinical pharmacology. Heidelberg: Springer 2020; pp. 637-67.
[http://dx.doi.org/10.1007/978-3-319-56637-5_72-1]
[39]
Bogacheva MS, Bystriakova MA, Lou Y-R. Thyroid hormone effect on the differentiation of human induced pluripotent stem cells into hepatocyte-like cells. Pharmaceuticals 2021; 14(6): 544.
[http://dx.doi.org/10.3390/ph14060544] [PMID: 34200130]
[40]
Hassani S-N, Moradi S, Taleahmad S, Braun T, Baharvand H. Transition of inner cell mass to embryonic stem cells: Mechanisms, facts, and hypotheses. Cell Mol Life Sci 2019; 76(5): 873-92.
[http://dx.doi.org/10.1007/s00018-018-2965-y] [PMID: 30420999]
[41]
Shouman S, Hussein AE, Essawy M, Abdelfattah-Hassan A, El-Badri N. Embryonic and pluripotent stem cells. In: Abdelkodous NE-B, Ed. Regenerative medicine and stem cell biology. Heidelberg: Springer 2020; pp. 37-65.
[http://dx.doi.org/10.1007/978-3-030-55359-3_2]
[42]
Haridhasapavalan KK, Raina K, Dey C, Adhikari P, Thummer RP. An insight into reprogramming barriers to iPSC generation. Stem Cell Rev Rep 2020; 16(1): 56-81.
[http://dx.doi.org/10.1007/s12015-019-09931-1] [PMID: 31758374]
[43]
Qiao Y, Agboola OS, Hu X, Wu Y, Lei L. Tumorigenic and immunogenic properties of induced pluripotent stem cells: A promising cancer vaccine. Stem Cell Rev Rep 2020; 16(6): 1049-61.
[http://dx.doi.org/10.1007/s12015-020-10042-5] [PMID: 32939647]
[44]
King NMP, Perrin J. Ethical issues in stem cell research and therapy. Stem Cell Res Ther 2014; 5(4): 85.
[http://dx.doi.org/10.1186/scrt474] [PMID: 25157428]
[45]
Poulos J. The limited application of stem cells in medicine: A review. Stem Cell Res Ther 2018; 9(1): 1.
[http://dx.doi.org/10.1186/s13287-017-0735-7] [PMID: 29291747]
[46]
O’Keeffe F, McGovern K. The political debate on embryo research in Australia and the role of religious actors and arguments. In: M Weiberg-Salzmann, U Willems, Eds. Religion and Biopolitics. Springer 2020; pp. 161-88.
[http://dx.doi.org/10.1007/978-3-030-14580-4_8]
[47]
Moradi S, Mahdizadeh H, Šarić T, et al. Research and therapy with induced pluripotent stem cells (iPSCs): social, legal, and ethical considerations. Stem Cell Res Ther 2019; 10(1): 341-1.
[http://dx.doi.org/10.1186/s13287-019-1455-y] [PMID: 31753034]
[48]
Pettinato G, Ramanathan R, Fisher RA, Mangino MJ, Zhang N, Wen X. Scalable differentiation of human iPSCs in a multicellular spheroid-based 3D culture into hepatocyte-like cells through direct Wnt/β-catenin pathway inhibition. Sci Rep 2016; 6: 32888.
[http://dx.doi.org/10.1038/srep32888] [PMID: 27616299]
[49]
Li S, Huang S-Q, Zhao Y-X, Ding Y-J, Ma D-J, Ding Q-R. Derivation and applications of human hepatocyte-like cells. World J Stem Cells 2019; 11(8): 535-47.
[http://dx.doi.org/10.4252/wjsc.v11.i8.535] [PMID: 31523372]
[50]
Hannan NR, Segeritz C-P, Touboul T, Vallier L. Production of hepatocyte-like cells from human pluripotent stem cells. Nat Protoc 2013; 8(2): 430-7.
[http://dx.doi.org/10.1038/nprot.2012.153] [PMID: 23424751]
[51]
Forouzesh M, Hosseini M, Ataei M, Farzaneh M, Khoshnam SE. An extracellular matrix-based culture system for generation of human pluripotent stem cell derived-hepatocytes. Curr Stem Cell Res Ther 2020. Epub ahead of print.
[http://dx.doi.org/10.2174/1574888X16666201228144834] [PMID: 33371861]
[52]
Corbett JL, Duncan SA. iPSC-derived hepatocytes as a platform for disease modeling and drug discovery. Front Med 2019; 6: 265-5.
[http://dx.doi.org/10.3389/fmed.2019.00265] [PMID: 31803747]
[53]
Chun YS, Chaudhari P, Jang Y-Y. Applications of patient-specific induced pluripotent stem cells; focused on disease modeling, drug screening and therapeutic potentials for liver disease. Int J Biol Sci 2010; 6(7): 796-805.
[http://dx.doi.org/10.7150/ijbs.6.796] [PMID: 21179587]
[54]
Huang C-S, Lin H-C, Lu K-H, et al. Generation of high quality of hepatocyte-like cells from induced pluripotent stem cells with Parp1 but lacking c-Myc. J Chin Med Assoc 2018; 81(10): 871-7.
[http://dx.doi.org/10.1016/j.jcma.2018.06.002] [PMID: 30017813]
[55]
Donato MT, Tolosa L. Stem-cell derived hepatocyte-like cells for the assessment of drug-induced liver injury. Differentiation 2019; 106: 15-22.
[http://dx.doi.org/10.1016/j.diff.2019.02.004] [PMID: 30844688]
[56]
Malhotra P, Shukla M, Meena P, et al. Mesenchymal stem cells are prospective novel off-the-shelf wound management tools. Drug Deliv Transl Res 2021; 1-26. Epub ahead of print.
[PMID: 33580481]
[57]
Ullah I, Subbarao RB, Rho GJ. Human mesenchymal stem cells - current trends and future prospective. Biosci Rep 2015; 35(2): e00191.
[http://dx.doi.org/10.1042/BSR20150025] [PMID: 25797907]
[58]
Lu M, Guo J, Wu B, et al. Mesenchymal stem cell-mediated mitochondrial transfer: A therapeutic approach for ischemic stroke. Transl Stroke Res 2020; 12(2): 212-29.
[http://dx.doi.org/10.1007/s12975-020-00853-6] [PMID: 32975692]
[59]
Zhou X, Cui L, Zhou X, et al. Induction of hepatocyte-like cells from human umbilical cord-derived mesenchymal stem cells by defined microRNAs. J Cell Mol Med 2017; 21(5): 881-93.
[http://dx.doi.org/10.1111/jcmm.13027] [PMID: 27874233]
[60]
Afshari A, Shamdani S, Uzan G, Naserian S, Azarpira N. Different approaches for transformation of mesenchymal stem cells into hepatocyte-like cells. Stem Cell Res Ther 2020; 11(1): 54.
[http://dx.doi.org/10.1186/s13287-020-1555-8] [PMID: 32033595]
[61]
O’Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol 2018; 9: 402.
[http://dx.doi.org/10.3389/fendo.2018.00402] [PMID: 30123182]
[62]
Valinezhad Orang A, Safaralizadeh R, Kazemzadeh-Bavili M. Mechanisms of miRNA-mediated gene regulation from common downregulation to mRNA-specific upregulation. Int J Genomics 2014; 2014: 970607-7.
[http://dx.doi.org/10.1155/2014/970607] [PMID: 25180174]
[63]
Vaschetto LM. miRNA activation is an endogenous gene expression pathway. RNA Biol 2018; 15(6): 826-8.
[http://dx.doi.org/10.1080/15476286.2018.1451722] [PMID: 29537927]
[64]
Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol 2006; 13(12): 1097-101.
[http://dx.doi.org/10.1038/nsmb1167] [PMID: 17099701]
[65]
Gregory RI, Chendrimada TP, Cooch N, Shiekhattar R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 2005; 123(4): 631-40.
[http://dx.doi.org/10.1016/j.cell.2005.10.022] [PMID: 16271387]
[66]
Zeng C, Xia J, Chen X, Zhou Y, Peng M, Zhang W. MicroRNA- like RNAs from the same miRNA precursors play a role in cassava chilling responses. Sci Rep 2017; 7(1): 17135.
[http://dx.doi.org/10.1038/s41598-017-16861-w] [PMID: 29214993]
[67]
Wu K, He J, Pu W, Peng Y. The role of exportin-5 in microRNA biogenesis and cancer. Genom Proteom Bioinform 2018; 16(2): 120-6.
[http://dx.doi.org/10.1016/j.gpb.2017.09.004] [PMID: 29723684]
[68]
Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 2014; 15(8): 509-24.
[http://dx.doi.org/10.1038/nrm3838] [PMID: 25027649]
[69]
Graves P, Zeng Y. Biogenesis of mammalian microRNAs: A global view. Genomics Proteomics Bioinformatics 2012; 10(5): 239-45.
[http://dx.doi.org/10.1016/j.gpb.2012.06.004] [PMID: 23200133]
[70]
Fareh M, Yeom K-H, Haagsma AC, Chauhan S, Heo I, Joo C. TRBP ensures efficient Dicer processing of precursor microRNA in RNA-crowded environments. Nat Commun 2016; 7: 13694.
[http://dx.doi.org/10.1038/ncomms13694] [PMID: 27934859]
[71]
Pu M, Chen J, Tao Z, et al. Regulatory network of miRNA on its target: Coordination between transcriptional and post-transcriptional regulation of gene expression. Cell Mol Life Sci 2019; 76(3): 441-51.
[http://dx.doi.org/10.1007/s00018-018-2940-7] [PMID: 30374521]
[72]
Lam JKW, Chow MYT, Zhang Y, Leung SWS. siRNA versus miRNA as therapeutics for gene silencing. Mol Ther Nucleic Acids 2015; 4: e252.
[http://dx.doi.org/10.1038/mtna.2015.23] [PMID: 26372022]
[73]
Messina A, Luce E, Hussein M, Dubart-Kupperschmitt A. Pluripotent-stem-cell-derived hepatic cells: hepatocytes and organoids for liver therapy and regeneration. Cells 2020; 9(2): 420.
[http://dx.doi.org/10.3390/cells9020420] [PMID: 32059501]
[74]
Fischer L, Lucendo-Villarin B, Hay DC, O’Farrelly C. Human PSC-derived hepatocytes express low levels of viral pathogen recognition receptors, but are capable of mounting an effective innate immune response. Int J Mol Sci 2020; 21(11): 3831.
[http://dx.doi.org/10.3390/ijms21113831] [PMID: 32481600]
[75]
Ruangrung K, Chakritbudsabong W, Rungarunlert S, et al. Analysis of Tembusu virus infection of human cell lines and human induced pluripotent stem cell derived hepatocytes. Virus Res 2021; 292: 198252.
[http://dx.doi.org/10.1016/j.virusres.2020.198252] [PMID: 33290792]
[76]
Nghiem-Rao TH, Pfeifer C, Asuncion M, et al. Human induced pluripotent stem cell derived hepatocytes provide insights on parenteral nutrition associated cholestasis in the immature liver. Sci Rep 2021; 11(1): 12386.
[http://dx.doi.org/10.1038/s41598-021-90510-1] [PMID: 34117281]
[77]
Mitani S, Takayama K, Nagamoto Y, et al. Human ESC/iPSC-derived hepatocyte-like cells achieve zone-specific hepatic properties by modulation of WNT signaling. Mol Ther 2017; 25(6): 1420-33.
[http://dx.doi.org/10.1016/j.ymthe.2017.04.006] [PMID: 28462819]
[78]
Farzaneh Z, Pournasr B, Ebrahimi M, Aghdami N, Baharvand H. Enhanced functions of human embryonic stem cell-derived hepatocyte-like cells on three-dimensional nanofibrillar surfaces. Stem Cell Rev Rep 2010; 6(4): 601-10.
[http://dx.doi.org/10.1007/s12015-010-9179-5] [PMID: 20694582]
[79]
Yu Y, Liu H, Ikeda Y, et al. Hepatocyte-like cells differentiated from human induced pluripotent stem cells: relevance to cellular therapies. Stem Cell Res 2012; 9(3): 196-207.
[http://dx.doi.org/10.1016/j.scr.2012.06.004] [PMID: 22885101]
[80]
Williams DP. Application of hepatocyte-like cells to enhance hepatic safety risk assessment in drug discovery. Philos Trans R Soc Lond B Biol Sci 2018; 373(1750): 373.
[http://dx.doi.org/10.1098/rstb.2017.0228] [PMID: 29786562]
[81]
Khosravi M, Azarpira N, Shamdani S, Hojjat-Assari S, Naserian S, Karimi MH. Differentiation of umbilical cord derived mesenchymal stem cells to hepatocyte cells by transfection of miR-106a, miR-574-3p, and miR-451. Gene 2018; 667: 1-9.
[http://dx.doi.org/10.1016/j.gene.2018.05.028] [PMID: 29763649]
[82]
Möbus S, Yang D, Yuan Q, et al. MicroRNA-199a-5p inhibition enhances the liver repopulation ability of human embryonic stem cell-derived hepatic cells. J Hepatol 2015; 62(1): 101-10.
[http://dx.doi.org/10.1016/j.jhep.2014.08.016] [PMID: 25135862]
[83]
Davoodian N, Lotfi AS, Soleimani M, Mowla SJ. MicroRNA-122 overexpression promotes hepatic differentiation of human adipose tissue-derived stem cells. J Cell Biochem 2014; 115(9): 1582-93.
[http://dx.doi.org/10.1002/jcb.24822] [PMID: 24733606]
[84]
Cui L, Shi Y, Zhou X, et al. A set of microRNAs mediate direct conversion of human umbilical cord lining-derived mesenchymal stem cells into hepatocytes. Cell Death Dis 2013; 4: e918-8.
[http://dx.doi.org/10.1038/cddis.2013.429] [PMID: 24232094]
[85]
Raut A, Khanna A. Enhanced expression of hepatocyte-specific microRNAs in valproic acid mediated hepatic trans-differentiation of human umbilical cord derived mesenchymal stem cells. Exp Cell Res 2016; 343(2): 237-47.
[http://dx.doi.org/10.1016/j.yexcr.2016.03.015] [PMID: 27001466]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy